Select a community
Fibromyalgia And Chronic Fatigue Syndrome
Find out more about the PatientsLikeMe
Fibromyalgia And Chronic Fatigue Syndrome Community
Home > Community Treatment Reports > Desvenlafaxine Treatment Report
What is Desvenlafaxine?

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is an extended release formulation believed to treat depression by affecting the levels of serotonin and norepinephrine, two neurotransmitters associated with depression.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Depression 14 5
Anxiety 4 2
Fibromyalgia 4 1
Pain 4 0
Body Aches 2 0
Fatigue 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 13%
Moderate
1 13%
Mild
1 13%
None
5 63%

Most commonly reported side effects

Random Tiredness/Energy
2 25%
Sluggishness
2 25%
Depression with suicidal thoughts
1 13%
sweating
1 13%
nausea, dizziness
1 13%
  • Mild
  • Moderate
  • Severe

Dosages

  1 other daily 30 mg daily 50 mg daily 100 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 16 Number of Patients: 16 5 Number of Patients: 5  

Stop Reasons

Why Patients Stopped Taking Desvenlafaxine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
1 25% Did not seem to work: 25%
Expense
1 25% Expense: 25%
Other
1 25% Other: 25%

See all 3 patients who’ve stopped taking Desvenlafaxine

Currently Taking Desvenlafaxine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
6
6
3
1

Stopped Taking Desvenlafaxine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
2
1
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
6 75%
Usually
0 0%
Sometimes
0 0%
Never
2 25%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
2 25%
A little
0 0%
Not at all
6 75%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
2 25%
$25-49
2 25%
< $25
2 25%

Report created on November 22, 2009.